|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Relationships between adenomatous polyposis coli (APC) mutations, BRAF V600E mutations, and the CpG island methylator phenotype (CIMP) in colon cancer have not been explored.
|
17293392 |
2007 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with advanced TNM (P < 0.001), more distant metastases (P = 0.025), and worse overall survival (OS, P < 0.001; multivariate HR = 4.2, P = 0.004) in colon cancer patients.
|
25367198 |
2014 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A set of 668 stage II and III CC samples from the PETACC-3 (Pan-European Trails in Alimentary Tract Cancers) clinical trial were used to assess differential gene expression between c.1799T>A (p.V600E) BRAF mutant and non-BRAF, non-KRAS mutant cancers (double wild type) and to construct a gene expression-based classifier for detecting BRAF mutant samples with high sensitivity.
|
22393095 |
2012 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The clinical studies in the manuscript by Al-Marrawi et al. describe the rational combination of signaling inhibitors in a colon cancer patient whose tumor cells express a mutant active B-RAF V600E protein that signals into the MEK1/2-ERK1/2 pathway downstream of K-RAS; this is a particularly aggressive form of colon cancer for which few rational therapeutic interventions have been available until recent times.
|
24025253 |
2013 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, this same agent does not generally benefit colon cancer patients who have the BRAF(V600E) mutation.
|
23074264 |
2012 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.
|
18519771 |
2008 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
MSI and the BRAF(V600E) mutation have a prognostic impact in colon cancer.
|
24964758 |
2014 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
|
29127628 |
2019 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Colon carcinoma BRAF V600E HT29 cells exhibited poor response to radiation compared to BRAF wild-type COLO320 and HCT116 cells.
|
29663854 |
2018 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A colon cancer cell line with RNF43-G659Vfs*41 and BRAF-V600E mutations was sensitive to activation of Wnt/β-catenin signaling.
|
31811196 |
2019 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation and 5 CpG island markers (MINT1, MINT2, MINT31, p16 and hMLH1) were assessed in 1154 cases of colon cancer.
|
17096326 |
2007 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We investigated the role of BRAF activating mutation (BRAF-V600E) in colorectal tumourigenesis by studying the effects of forced expression of BRAF-V600E in the 'normal' colon epithelial NCM460 cell line and by targeting endogenous BRAF-V600E in MSI-High (MSI-H) colon cancer cell lines.
|
17427169 |
2007 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation is reportedly associated with inferior survival among colon cancer patients.
|
25636897 |
2015 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The mutational status of KRAS and BRAF(V600E) oncogenes combined with analysis of the DNA mismatch repair system with/without the CpG island methylator phenotype (CIMP) has been shown to identify colon cancer subtypes with distinct clinical features and prognoses.
|
26872400 |
2016 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
|
24832158 |
2014 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Sorafenib and cetuximab therapy led to a mixed radiographic response with some areas showing dramatic improvement and other areas showing stable disease over a 7-month period which is a notably long period of progression-free survival for V600E BRAF mutated colon cancer.
|
23792568 |
2013 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF (V600E) and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147).
|
26160882 |
2015 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
KRAS and BRAF (V600E) mutations are important predictive and prognostic markers, respectively, in colon cancer, but little is known about patient and clinical factors associated with them.
|
24925349 |
2014 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Vemurafenib is a B-Raf V600E inhibitor that exerts significant inhibitory effects in melanoma but not in colon cancer, and the mechanism of vemurafenib resistance remains unclear.
|
30872078 |
2019 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In microsatellite stable tumors, homozygous carriers of the G39E polymorphism had an increased risk of CIMP+ colon cancer (odds ratio (OR) 2.2, 95% confidence interval (CI) 1.1, 4.2) and BRAF V600E mutation (OR 3.1, 95% CI 1.01, 9.7) in a case-control comparison.
|
19582761 |
2009 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
|
22281684 |
2012 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results highlight the need to evaluate the action of glucocorticoid on cancer progression in melanoma, thyroid and colon carcinoma in which B-RAF-V600E is a frequent oncogene, and cancers in which evasion from senescence has been shown.
|
31371485 |
2019 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
|
31185985 |
2019 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, the cluster drawn by the two mutations of V600E and E542K showed that all samples with those mutations belonged to the right-sided colon cancer group.
|
29556349 |
2018 |
|
Colon Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We reproducibly associate higher expression of the ligand-receptor axis of TFF2 and CXCR4 with BRAF V600E-mutant colon cancer (P = 3.0 × 10(-3) and 0.077, respectively for TCGA; P = 3.0 × 10(-8) and 5.1 × 10(-7) for CIT).
|
25899003 |
2015 |